(N(1),N(12))bis(ethyl)- 6,7- dehydrospermine

01/01/2020 - "This report describes the first phase I clinical trial to investigate PG-11047 in patients with advanced refractory metastatic solid tumors. "
01/01/2021 - "This report describes a Phase Ib clinical trial investigating PG-11047 in combination with cytotoxic and anti-angiogenic chemotherapeutic agents in patients with advanced refractory metastatic solid tumors or lymphoma. "
01/01/2020 - "A phase I dose-escalation study of the polyamine analog PG-11047 in patients with advanced solid tumors."
01/01/2017 - "Through its effects on polyamine metabolism, PG-11047 effectively inhibits tumor growth in cancer cell lines of multiple origins as well as in human tumor mouse xenografts. "
05/01/2009 - "Gene expression analysis of HCT116 colon tumor-derived cells treated with the polyamine analog PG-11047."

01/01/2017 - "Following exposure of lung cancer cell lines to Nano11047, uptake and intracellular degradation into the parent compound PG-11047 was observed. "
05/01/2009 - "The conformationally restricted polyamine analog PG-11047 has significant growth inhibitory activity against prostate and lung cancer cell lines and is currently under evaluation in several clinical trials, both alone and in combination with other drugs, for the treatment of relapsed or refractory cancer. "

01/01/2021 - "This report describes a Phase Ib clinical trial investigating PG-11047 in combination with cytotoxic and anti-angiogenic chemotherapeutic agents in patients with advanced refractory metastatic solid tumors or lymphoma. "
01/01/2021 - "A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma."

05/01/2009 - "The objective of this study was to identify the molecular signature of genes responsive to PG-11047 treatment and the biochemical effects of this drug in the HCT116 colon cancer cell line. "
05/01/2009 - "These data show that PG-11047 has a broad spectrum of anticancer activity in colon cancer cells."

12/14/2009 - "A systems analysis of the chemosensitivity of breast cancer cells to the polyamine analogue PG-11047."
12/14/2009 - "The objective of this study was to use a systems approach to study the relative effects of PG-11047, a polyamine analogue, across breast cancer cells derived from different patients and to identify genetic markers associated with differential cytotoxicity. "